{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:25:23Z","timestamp":1793849123563,"version":"4.6.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clinthera.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:28:13Z","timestamp":1785410893000},"page":"1151-1159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatitis Associated With Givosiran: A Real-World Pharmacovigilance Study Based on the FAERS and EudraVigilance Databases"],"prefix":"10.1016","volume":"48","author":[{"given":"Fang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-485X","authenticated-orcid":false,"given":"Pengqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.07.002_bib0001","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0003","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3390\/jcm12093091","article-title":"Intrahepatic cholangiocarcinoma and acute intermittent porphyria: a case report","volume":"12","author":"Guida","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0004","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/ph15060675","article-title":"Pharmacovigilance signals of the opioid epidemic over 10 years: data mining methods in the analysis of pharmacovigilance datasets collecting adverse drug reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/ph19010155","article-title":"Resistance, ineffectiveness, and off-label use related to cephalosporins from the reserve group\u2014a pharmacovigilance signal detection study on EudraVigilance database","volume":"19","author":"Arseniu","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0006","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7150\/ijms.8.487","article-title":"Adverse event profiles of platinum agents: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations","volume":"8","author":"Sakaeda","year":"2011","journal-title":"Int J Med Sci"},{"issue":"3","key":"10.1016\/j.clinthera.2026.07.002_bib0007","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1097\/JS9.0000000000004502","article-title":"Association between opioid analgesics and learning disorders: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases","volume":"112","author":"Feng","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1765071","article-title":"Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases","volume":"17","author":"Gong","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0009","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0962280211403602","article-title":"Disproportionality methods for pharmacovigilance in longitudinal observational databases","volume":"22","author":"Zorych","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0011","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0013","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0016","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1737359","article-title":"Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data","volume":"16","author":"Yang","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0018","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.07.002_bib0019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:36:05Z","timestamp":1793846165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0149291826002638"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.07.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pancreatitis Associated With Givosiran: A Real-World Pharmacovigilance Study Based on the FAERS and EudraVigilance Databases","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}